Article

Raltegravir 1200 mg Once Daily as Maintenance Therapy in Virologically Suppressed HIV-1 Infected Adults : QDISS Open-Label Trial

2021-08-30

Abstract excerpt

<h4>Background: </h4> Raltegravir (RAL) has favorable tolerability and safety profile, with few and manageable drug interactions. The use of RAL 1200 mg once daily (qd) for first-line therapy is well established. We assessed efficacy and safety of RAL 1200 mg qd, as part of triple cART, for maintenance strategy. <h4>Methods:</h4> The QDISS trial (NCT03195452) was a 48-week multicenter, single-arm, open-label study...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 46f05b55-7bd9-552a-9656-b28686fccdd2
DOI: 10.21203/rs.3.rs-823865/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Raltegravir 1200 mg Once Daily as Maintenance Therapy in Virologically Suppressed HIV-1 Infected Adults : QDISS Open-Label TrialDOI 10.21203/rs.3.rs-823865/v1Read

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)Semantic proximity Read

Dolutegravir plus lamivudine for the treatment of HIV-1 infection.Semantic proximity Read

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.Semantic proximity Read

Clinical outcomes of Dolutegravir treatment in people living with HIV in Brazil: Protocol for the CODE CohortSemantic proximity Read

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.Semantic proximity Read

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.Semantic proximity Read

Metabolic Effects of Switching from TAF/FTC/RPV to BIC/TAF/FTC in Real-World Clinical SettingSemantic proximity Read

Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance-associated mutations.Semantic proximity Read

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.Semantic proximity Read

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.Semantic proximity Read

The dolutegravir failure cohort: a multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocolSemantic proximity Read

The pharmacokinetics, pharmacodynamics and pharmacogenetics of Dolutegravir and Cobicistat in the treatment of HIVSemantic proximity Read